Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Accumulated Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Accumulated Expenses for 12 consecutive years, with $398000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 61.51% to $398000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $398000.0, a 61.51% decrease, with the full-year FY2025 number at $1.4 million, up 68.38% from a year prior.
  • Accumulated Expenses was $398000.0 for Q3 2025 at IGC Pharma, down from $792000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.8 million in Q4 2024 to a low of $398000.0 in Q3 2025.
  • A 3-year average of $1.0 million and a median of $816000.0 in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 144.56% in 2024, then tumbled 61.51% in 2025.
  • IGC Pharma's Accumulated Expenses stood at $745000.0 in 2023, then soared by 144.56% to $1.8 million in 2024, then plummeted by 78.16% to $398000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Accumulated Expenses are $398000.0 (Q3 2025), $792000.0 (Q2 2025), and $1.4 million (Q1 2025).